ROCKVILLE, Md., April 30, 2019 /PRNewswire/ -- REGENXBIO Inc.
(Nasdaq: RGNX), a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy based on its proprietary NAV® Technology
Platform, today announced that it will host a conference call on
Tuesday, May 7, 2019, at 4:30 p.m. ET to discuss its financial results for
the quarter ended March 31, 2019, and
recent operational highlights.
To access the live call by phone, dial (855) 422-8964 (domestic)
or (210) 229-8819 (international) and enter the passcode 6379973.
To access a live or recorded webcast of the call, please visit the
Investors section of the REGENXBIO website at www.regenxbio.com.
The recorded webcast will be available for approximately 30 days
following the call.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. REGENXBIO's NAV Technology Platform, a proprietary
adeno-associated virus (AAV) gene delivery platform, consists of
exclusive rights to more than 100 novel AAV vectors, including
AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV
Technology Platform Licensees are applying the NAV Technology
Platform in the development of a broad pipeline of candidates in
multiple therapeutic areas.
CONTACT:
Investors
Heather
Savelle, 212-600-1902
heather@argotpartners.com
Media
David Rosen,
212-600-1902
david.rosen@argotpartners.com
View original
content:http://www.prnewswire.com/news-releases/regenxbio-to-host-conference-call-on-may-7-to-discuss-first-quarter-2019-financial-results-and-recent-operational-highlights-300840244.html
SOURCE REGENXBIO Inc.